RxDoctor Payments Data

Rajiv Sood, MD

Internal Medicine · Hoffman Estates, ILNPI 1699738351

Payments from drug & device makers

$62,418in general payments, 2019–2025

Across 404 payments — averaging $154.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Avita Medical Americas, LLC$53K
  • Kerecis Limited$2K
  • AbbVie$1K
  • AstraZeneca$1K
  • Lilly USA, LLC$967
  • Johnson & Johnson$733
  • plus $4K from 36 others

What the payments were for

  • Consulting fees$40,75065%
  • Speaking & faculty fees$5001%
  • Travel & lodging$12,47520%
  • Food & beverage$8,37613%
  • Education$3171%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$62,418 in reported general payments places this provider in the 95th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$845,083
Medicare patients
804
Services billed
7,676

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban791$325,812
JardianceEmpagliflozin157$119,408
OzempicSemaglutide66$73,723
TrulicityDulaglutide74$70,423
JanuviaSitagliptin Phosphate92$63,977
XareltoRivaroxaban140$62,589
FarxigaDapagliflozin Propanediol62$60,724
MounjaroTirzepatide45$54,812
XifaxanRifaximin17$39,617
Sevelamer Carbonate113$31,912
Breo ElliptaFluticasone/Vilanterol66$30,950
NuedextaDextromethorphan Hbr/Quinidine18$24,230
MyrbetriqMirabegron89$22,791
Incruse ElliptaUmeclidinium Bromide55$20,283
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr40$19,784

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo$313$336,104823 claims
Boehringer IngelheimJardiance, Tradjenta$374$138,692197 claims
Lilly USA, LLCTrulicity, Mounjaro$967$125,234119 claims
GSKBreo Ellipta, Incruse Ellipta, Anoro Ellipta, Trelegy Ellipta$87$88,967185 claims
MerckJanuvia, Zerbaxa$50$80,337112 claims
Novo NordiskOzempic$587$73,72366 claims
Johnson & JohnsonXarelto$733$62,589140 claims
AstraZenecaFarxiga$1,105$60,72462 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$30$39,61717 claims
AbbVieAvycaz, Linzess$1,395$28,65428 claims
Astellas Pharma US IncMyrbetriq$214$22,79189 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Hoffman Estates

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →